These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1912765)

  • 1. Histomorphometric assessment of trabecular bone remodelling in osteoporosis.
    Compston JE; Croucher PI
    Bone Miner; 1991 Aug; 14(2):91-102. PubMed ID: 1912765
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone quality fills holes in fracture risk.
    Stokstad E
    Science; 2005 Jun; 308(5728):1580. PubMed ID: 15947173
    [No Abstract]   [Full Text] [Related]  

  • 3. Age- and menopause-related bone loss compromise cortical and trabecular microstructure.
    Seeman E
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1218-25. PubMed ID: 23833200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone histomorphometry in the pathophysiological evaluation of primary and secondary osteoporosis and various treatment modalities.
    Steiniche T
    APMIS Suppl; 1995; 51():1-44. PubMed ID: 7669370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
    Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
    J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
    Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
    J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histomorphometric analysis of glucocorticoid-induced osteoporosis.
    Dalle Carbonare L; Bertoldo F; Valenti MT; Zenari S; Zanatta M; Sella S; Giannini S; Cascio VL
    Micron; 2005; 36(7-8):645-52. PubMed ID: 16243531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Normal bone remodelling--what can go wrong in osteoporosis?].
    Midtby M; Magnus JH
    Tidsskr Nor Laegeforen; 1998 Feb; 118(4):552-7. PubMed ID: 9520583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis from the point of view of the clinical endocrinologist.
    Szũcs J
    Agents Actions; 1994 Mar; 41(1-2):80-3. PubMed ID: 8079825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings.
    Hein G; Weiss C; Lehmann G; Niwa T; Stein G; Franke S
    Ann Rheum Dis; 2006 Jan; 65(1):101-4. PubMed ID: 16344492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iliac trabecular bone formation predicts radial trabecular bone density changes in type 1 osteoporosis.
    Hesp R; Arlot ME; Edouard C; Bradbeer JN; Meunier PJ; Reeve J
    J Bone Miner Res; 1991 Sep; 6(9):929-35. PubMed ID: 1789140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of osteoporosis: new mechanistic insights.
    Armas LA; Recker RR
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):475-86. PubMed ID: 22877425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of bone loss and gain in untreated and treated osteoporosis.
    Compston J
    Endocrine; 2002 Feb; 17(1):21-7. PubMed ID: 12014699
    [No Abstract]   [Full Text] [Related]  

  • 15. [Assessment of bone quality--present and future].
    Ito M
    Clin Calcium; 2004 Dec; 14(12):27-32. PubMed ID: 15577170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone histology in postmenopausal osteoporosis--variations in cellular activity].
    Lozo P; Krpan D; Krvavica A; Vukelić Baturić T; Fistonić I; Kusec V
    Acta Med Croatica; 2004; 58(1):5-11. PubMed ID: 15125387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causes of age-related bone loss and bone fragility: an alternative view.
    Raisz LG; Seeman E
    J Bone Miner Res; 2001 Nov; 16(11):1948-52. PubMed ID: 11697790
    [No Abstract]   [Full Text] [Related]  

  • 18. Trabecular spacing in post-menopausal Australian women with and without vertebral fractures.
    Moore RJ; Durbridge TC; McNeil PJ; Parkinson IH; Need AG; Vernon-Roberts B
    Aust N Z J Med; 1992 Jun; 22(3):269-73. PubMed ID: 1386728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone histomorphometry;A role of evaluation for bone quality and mechanical strength].
    Yamamoto N; Takahashi H; Shimakura T
    Clin Calcium; 2016 Jan; 26(1):9-15. PubMed ID: 26728526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of bisphosphonates in involutional osteoporosis.
    Ott SM
    J Bone Miner Res; 1993 Dec; 8 Suppl 2():S597-606. PubMed ID: 8122531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.